Price Reductions for Interim Supplementary Cycle

Summary of 1 December 2012 Price Reductions for Interim Supplementary Cycle by Drug / Manner of Administration / Weighted Average Percentage Reduction.

Price Reductions for Interim Supplementary Cycle

Drug	Manner of Administration	Weighted Average Percentage Reduction
Docetaxel	Injection	76.20%
Pioglitazone	Oral	29.12%

For further information about specific prices for pharmaceutical items please see the Federal Register of Legislative Instruments (FRLI) at the following link:

http://www.comlaw.gov.au/Series/F2012L01731

Notes: Price Reductions for Risedronic Acid Oral and Docetaxel Injection

The Weighted Average Percentage Reductions previously published for Interim Supplementary Cycle have been amended, due to the outcome of a court case on 6 December 2012.

As a result of the outcome, there is no price reduction effective 1 December 2012 for Risedronic Acid Oral and a change has been made to the price reduction for Docetaxel Injection, from 76.83% to 76.20%.